The study aims to explore the prognostic assessment value of bone marrow plasma cell morphology, Vitamin D (Vit D), and Interleukin-6 (IL-6) in patients with Multiple Myeloma (MM), with the potential to provide local medical care for follow-up patients and indirectly alleviate the difficulty of accessing healthcare in higher-level hospitals. This evidence concerns the gene IL6 and plasma cell myeloma.